Elinor M Milder, MD | |
137 Main St, Suite 100, Medford, MA 02155 | |
(781) 395-4761 | |
(781) 395-5081 |
Full Name | Elinor M Milder |
---|---|
Gender | Female |
Speciality | Family Practice |
Experience | 12 Years |
Location | 137 Main St, Medford, Massachusetts |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1295097251 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 264841 (Massachusetts) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
North Shore Medical Center - | Salem, MA | Hospital |
Melrosewakefield Healthcare | Melrose, MA | Hospital |
Massachusetts General Hospital | Boston, MA | Hospital |
Lahey Hospital & Medical Center, Burlington | Burlington, MA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mass General Brigham Community Physicians Inc | 1759273436 | 297 |
News Archive
CSL Behring announced today it has been granted national marketing authorization in Italy and Luxembourg to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. This latest authorization brings the number of countries to 28 (in Europe, Asia, North America, South America and Australia) in which Berinert is now licensed.
The US Food and Drug Administration (FDA) has issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease (GERD), comparing anti-reflux surgery with either omeprazole (SOPRAN study) or NEXIUM (LOTUS study) treatment.
Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.
Queen's University assistant professor Pendar Farahani (Department of Medicine and Department of Public Health Sciences) is advocating the use of gender-based treatment for mitigating the cardiovascular risk factors related to diabetes.
Parents who are active during pregnancy and early in their child's life tend to raise more active children, finds a study published on bmj.com.
› Verified 5 days ago
Entity Name | Hallmark Health Medical Associates Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1770563900 PECOS PAC ID: 4385638782 Enrollment ID: O20040409000006 |
News Archive
CSL Behring announced today it has been granted national marketing authorization in Italy and Luxembourg to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. This latest authorization brings the number of countries to 28 (in Europe, Asia, North America, South America and Australia) in which Berinert is now licensed.
The US Food and Drug Administration (FDA) has issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease (GERD), comparing anti-reflux surgery with either omeprazole (SOPRAN study) or NEXIUM (LOTUS study) treatment.
Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.
Queen's University assistant professor Pendar Farahani (Department of Medicine and Department of Public Health Sciences) is advocating the use of gender-based treatment for mitigating the cardiovascular risk factors related to diabetes.
Parents who are active during pregnancy and early in their child's life tend to raise more active children, finds a study published on bmj.com.
› Verified 5 days ago
Entity Name | Mass General Brigham Community Physicians Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1548638265 PECOS PAC ID: 1759273436 Enrollment ID: O20151215000536 |
News Archive
CSL Behring announced today it has been granted national marketing authorization in Italy and Luxembourg to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. This latest authorization brings the number of countries to 28 (in Europe, Asia, North America, South America and Australia) in which Berinert is now licensed.
The US Food and Drug Administration (FDA) has issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease (GERD), comparing anti-reflux surgery with either omeprazole (SOPRAN study) or NEXIUM (LOTUS study) treatment.
Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.
Queen's University assistant professor Pendar Farahani (Department of Medicine and Department of Public Health Sciences) is advocating the use of gender-based treatment for mitigating the cardiovascular risk factors related to diabetes.
Parents who are active during pregnancy and early in their child's life tend to raise more active children, finds a study published on bmj.com.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Elinor M Milder, MD 137 Main St, Suite 100, Medford, MA 02155 Ph: (781) 395-4761 | Elinor M Milder, MD 137 Main St, Suite 100, Medford, MA 02155 Ph: (781) 395-4761 |
News Archive
CSL Behring announced today it has been granted national marketing authorization in Italy and Luxembourg to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. This latest authorization brings the number of countries to 28 (in Europe, Asia, North America, South America and Australia) in which Berinert is now licensed.
The US Food and Drug Administration (FDA) has issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease (GERD), comparing anti-reflux surgery with either omeprazole (SOPRAN study) or NEXIUM (LOTUS study) treatment.
Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.
Queen's University assistant professor Pendar Farahani (Department of Medicine and Department of Public Health Sciences) is advocating the use of gender-based treatment for mitigating the cardiovascular risk factors related to diabetes.
Parents who are active during pregnancy and early in their child's life tend to raise more active children, finds a study published on bmj.com.
› Verified 5 days ago
Poul M Laplante, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 92 High St, Suite Dh4, Medford, MA 02155 Phone: 781-306-0200 | |
Marie T. Walsh Condon, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 75 Riverside Ave, Suite 2, Medford, MA 02155 Phone: 781-306-0200 Fax: 781-306-0264 | |
Dr. Sarah W Morrison, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 137 Main St, Medford, MA 02155 Phone: 781-395-4761 Fax: 781-395-5081 | |
Dr. Leanne Lee, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 137 Main St, Medford, MA 02155 Phone: 781-395-4761 Fax: 781-345-5081 | |
Christine Anne Mulligan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 137 Main St, Medford, MA 02155 Phone: 781-395-4761 Fax: 781-395-5081 | |
Dr. Michael Barry Stevens, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 170 Governors Ave, Medford, MA 02155 Phone: 781-391-0801 Fax: 781-391-7936 |